Literature DB >> 11310807

Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.

B Rosón1, J Carratalà, F Tubau, J Dorca, J Liñares, R Pallares, F Manresa, F Gudiol.   

Abstract

Empirical antibiotic therapy of community-acquired pneumonia (CAP) has been complicated by the worldwide emergence of penicillin resistance among Streptococcus pneumoniae. The impact of this resistance on the outcome of patients hospitalized for CAP, empirically treated with betalactams, has not been evaluated in a randomized study. We conducted a prospective, randomized trial to assess the efficacy of amoxicillin-clavulanate (2 g/200 mg/8 hr) and ceftriaxone (1 g/24 hr) in a cohort of patients hospitalized for moderate-to-severe CAP. Three-hundred seventy-eight patients were randomized to receive amoxicillin-clavulanate (184 patients) or ceftriaxone (194 patients). Efficacy was assessed on Day 2, after completion of therapy and at long term follow-up. There were no significant differences in outcomes between treatment groups, both in intention-to-treat and per-protocol analysis. Overall mortality was 10.3% for amoxicillin-clavulanate and 8.8% for ceftriaxone (NS). There were 116 evaluable patients with proven pneumococcal pneumonia. Rates of high-level penicillin resistance (MIC of penicillin > or = 2 microg/mL) were similar in the two groups (8.2 and 10.2%). Clinical efficacy at the end of therapy was 90.6% for amoxicillin-clavulanate and 88.9% for ceftriaxone (95% C.I. of the difference: -9.3 to +12.7%). No differences in outcomes were attributable to differences in penicillin susceptibility of pneumococcal strains. Sequential i.v./oral amoxicillin-clavulanate and parenteral ceftriaxone were equally safe and effective for the empirical treatment of acute bacterial pneumonia, including penicillin and cephalosporin-resistant pneumococcal pneumonia. The use of appropriate betalactams in patients with penumococcal pneumonia and in the overall CAP population, is reliable at the current level of resistance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310807     DOI: 10.1089/107662901750152864

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  12 in total

Review 1.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

2.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

3.  High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia.

Authors:  Eric Batard; Nathalie Lecadet; Nicolas Goffinet; Jean-Benoit Hardouin; Didier Lepelletier; Gilles Potel; Emmanuel Montassier
Journal:  Infection       Date:  2015-05-22       Impact factor: 3.553

4.  In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations.

Authors:  Daniel F Sahm; Clyde Thornsberry; David C Mayfield; Mark E Jones; James A Karlowsky
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

6.  Increasing use of third-generation cephalosporins for pneumonia in the emergency department: may some prescriptions be avoided?

Authors:  N Goffinet; N Lecadet; M Cousin; C Peron; J-B Hardouin; E Batard; E Montassier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-18       Impact factor: 3.267

Review 7.  Community-acquired pneumonia.

Authors:  Mark Loeb
Journal:  BMJ Clin Evid       Date:  2010-08-18

8.  Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.

Authors:  E Pérez-Trallero; C Fernández-Mazarrasa; C García-Rey; E Bouza; L Aguilar; J García-de-Lomas; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections.

Authors:  N Fernández-Sabé; J Carratalà; J Dorca; B Rosón; F Tubau; F Manresa; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

Review 10.  Community-acquired pneumonia.

Authors:  Mark Loeb
Journal:  BMJ Clin Evid       Date:  2008-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.